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The vitamin D receptor (VDR) gene has been associated with cancer risk, but only a few polymorphisms have been studied in
relation to melanoma risk and the results have been inconsistent. We examined 38 VDR gene single nucleotide
polymorphisms (SNPs) in a large international multicenter population-based case-control study of melanoma. Buccal DNAs
were obtained from 1,207 people with incident multiple primary melanoma and 2,469 with incident single primary melanoma.
SNPs with known or suspected impact on VDR activity, haplotype tagging SNPs with 10% minor allele frequency in
Caucasians, and SNPs reported as significant in other association studies were examined. Logistic regression was used to
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calculate the relative risks conferred by the individual SNP. Eight of 38 SNPs in the promoter, coding, and 30 gene regions
were individually significantly associated with multiple primary melanoma after adjusting for covariates. The estimated
increase in risk for individuals who were homozygous for the minor allele ranged from 25 to 33% for six polymorphisms:
rs10875712 (odds ratios [OR] 1.28; 95% confidence interval (CI), 1.01–1.62), rs4760674 (OR 1.33; 95% CI, 1.06–1.67),
rs7139166 (OR 1.26; 95%CI, 1.02–1.56), rs4516035 (OR 1.25; 95%CI, 1.01–1.55), rs11168287 (OR 1.27; 95%CI, 1.03–1.57)
and rs1544410 (OR 1.30; 95%CI, 1.04–1.63); for two polymorphisms, homozygous carriers had a decreased risk: rs7305032
(OR 0.81; 95%CI 0.65–1.02) and rs7965281 (OR, 0.78; 95%CI, 0.62–0.99). We recognize the potential false positive findings
because of multiple comparisons; however, the eight significant SNPs in our study outnumbered the two significant tests
expected to occur by chance. The VDR may play a role in melanomagenesis.
Vitamin D is hypothesized to lower the risk for or mortality
from several cancers, including melanoma. In vitro and in
vivo assays show that vitamin D modulates cell proliferation,
differentiation and programmed cell death,1–5 supporting its
anticarcinogenic potential. A number of observational studies
in humans have also suggested that vitamin D, or putative
surrogates for vitamin D status such as season, geographic
latitude and evidence of chronic sun exposure, is associated
with better outcomes in melanoma patients, despite the fact
that UVB exposure, which activates the precursor of vitamin
D present in skin, is a known risk factor for melanomagene-
sis.6–9 This adds to the plausibility of the hypothesis that
vitamin D affects melanoma risk.
The active form of Vitamin D, 1,25-dihydroxyvitamin D,
exerts its biological function by binding to the vitamin D re-
ceptor (VDR), a nuclear steroid hormone receptor expressed
in many tissues and organs including skin.10 This receptor is
encoded by the vitamin D receptor gene (ID 7421, OMIM
601769), which spans approximately 100 Kb on chromosome
12q13.11, with a large noncoding region spanning exons 1F
to 1C, and with exons 2–9 encoding a 424 aminoacid pro-
tein.11 The VDR gene contains numerous variants, some of
which are hypothesized to inﬂuence the expression and/or
function of the VDR protein product, and some of which
have been associated with complex traits and diseases such as
osteoporosis, diabetes, small stature and cancer.12,13
Despite the large number of single nucleotide polymor-
phisms (SNPs), to date only a few common polymorphisms
in the VDR gene have been studied in relation to melanoma
risk: FokI, BsmI, TaqI, ApaI, A-1012G and Cdx2, and the
results for some of the SNPs have not been consistent across
different studies.14–23 For example, the FokI (rs2228570)
minor allele T (f, M4) results in production of a VDR protein
that is less effective as a transcriptional activator24–26 and has
been linked to an increased risk for melanoma in several
studies,14,16,21,23 and in pooled analyses,23,27,28 but has been
observed to have no effect according to other reports.19,20,22,23
Some of the inconsistencies may be due to differences in the
study design, in study populations or in the exposures or
adjustments for covariates during the analyses. It is also pos-
sible, especially when the size of the VDR gene region is con-
sidered, that the causal genetic variant or key group of var-
iants remains to be identiﬁed.
Nejentsev et al.12 identiﬁed the minimal set of tag SNPs
and then evaluated the informativeness of the most com-
monly studied VDR SNPs in relation to disease association.
The authors found that FokI was not in linkage disequili-
brium (LD) with any other SNP, while ApaI, TaqI and BsmI
predicted only 38% of the SNPs in ‘‘block B’’ with R2 > 0.8.
Therefore, in studies that genotyped only FokI, TaqI, BsmI
or ApaI, information on a large fraction of common SNPs
was not captured. The aim of this study was to conduct a
comprehensive analysis of common genetic variants including
less studied SNPs across the VDR gene and to determine
their effects on melanoma risk.
Material and Methods
Study population
Subjects were recruited between 1998 and 2003 through an
international multicenter population-based case control study
of multiple primary melanoma, the Genes, Environment and
Melanoma Study (GEM). The GEM population consists of
incident cases of multiple primary melanoma identiﬁed in
eight population-based registries and one hospital center in
Australia, Canada, Italy and United States. Patients with inci-
dent single primary melanoma were used as controls. This
design is, in effect, a case-control study of melanoma con-
ducted in the high risk population of individuals who have
already experienced a melanoma diagnosis. Further details of
the study design and its rationale have been published.29,30
The study was approved by the institutional review boards
at all centers. All study participants signed informed consent,
provided a buccal sample for extraction of germline DNA
and completed a detailed interview, providing information on
sun exposure history, sun sensitivity and phenotypic
characteristics.
Selection of VDR SNPs
DNA samples from 1,207 individuals with multiple primary
melanoma and 2,469 with single primary melanoma were
available for genotyping. A total of 42 SNPs located on aver-
age at 3.6 Kb from each other were selected. These included
haplotype tagging SNPs with minor allele frequency (MAF)
>10% in Caucasians,12,13 SNPs with known or suspected
impact on the transcription, stability and/or activity of the
VDR and SNPs reported as signiﬁcant in other association
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studies. Speciﬁcally, rs11568820 located on the promoter has
been found to affect transcription of VDR by interfering with
the binding site of the transcription factor Cdx2.11 SNPs
rs7139166 (1A-1521) and rs4516035 (1A-1012), when the
haplotype 1521G/-1012A is present, were shown to affect
promoter activity.31 The polymorphism rs2228570 (FokI) re-
sponsible for an alternative earlier start and a less active pro-
tein was included. The commonly studied polymorphisms
rs731236 (TaqI) and rs1544410 (BsmI) were also included,
although their functional impact is less apparent.
Laboratory methods
The isolation of DNA was described previously.32 We used
the Sequenom MassARRAY iPLEX genotyping Platform
(Sequenom, San Diego, CA)33 to test 36 SNPs and pyrose-
quencing and melting temperature analysis to test two SNPs.
For iPLEX, experiments were designed with the RealSNP
Assay Database and the MassArray software v.3.4. Five to 10
ng of genomic DNA were ampliﬁed using speciﬁc primers,
reagents and cycling conditions detailed in the Supporting
Information (Table S1). Products were spotted onto 384
SpectroCHIP bioarrays (Sequenom). Cluster plots were eval-
uated with the TyperAnalyzer application (MassARRAY
v.3.4). Assays were considered optimal according to degree of
clustering, absence of signal in the blanks and when sequenc-
ing of representative samples within the clusters conﬁrmed
the genotypes. Four SNPs were rejected during the assay
design or during the wet testing because of nonspeciﬁc sig-
nals (rs2238139, rs739837) or very low signals and call rates
(rs2408876, rs3847987). SNPs rs2228570 (267bp) and
rs1544410 (209bp) were genotyped using single SNP geno-
typing methods: melting temperature analysis34 coupled to
the LightTyper (Roche Applied Science, Indianapolis, IN)
and pyrosequencing35 with the PSQTM MA instrument (Biot-
age AB, Uppsala, Sweden). Speciﬁc primers and probes, reac-
tion and cycling conditions are available in Supporting Infor-
mation Table S1. Quality control (QC) procedures included
use of barcodes on samples and plates, inclusion of internal
laboratory controls, randomly selected repeats (5% for Mas-
sArray and 10% for pyrosequencing and for melting tempera-
ture analyses), pre-polymerase chain reaction (PCR) dedi-
cated materials and working space and at least two
independent readers for review and interpretation of cluster
plots, pyrograms, melting curves and results. A plate contain-
ing discordant results for at least one pair of duplicate sam-
ples or internal controls was newly assayed. Samples with
weak signals and outliers were repeated. QC for data entry
included an additional review of 20% of genotype calls. There
was 100% agreement in the genotyping calls between two in-
dependent laboratory members. Direct sequencing was per-
formed on an independently ampliﬁed PCR fragment to con-
ﬁrm the genotype of laboratory control samples and when a
new SNP was identiﬁed by different sequence pattern in the
pyrogram or different melting proﬁle using standard
methods.36
Statistical analysis
We analyzed a total of 38 VDR SNPs in relation to risk of
melanoma using conventional methods for case-control stud-
ies. The ‘‘variant’’ allele was deﬁned to be the less frequently
occurring allele. For each SNP, logistic regression was used to
calculate adjusted odds ratios (OR) with 95% conﬁdence
intervals (95% CI). Heterozygous and homozygous carriers of
the variant allele were separately compared to homozygous
carriers of the most prevalent or ‘‘reference’’ allele within the
same SNP-speciﬁc logistic regression model. An ordinal vari-
able for the three possible genotypes was also created to eval-
uate linear trend. A multiplicative age–sex interaction term
was included in all models to control for the fact that the age
incidence curves for melanoma differ for men and women.
In addition to age, sex and age–sex interaction, study center
was included as a covariate in the multivariate analysis to
account for potential differences among populations. Analy-
ses further adjusting for known melanoma risk factors, such
as mole count, hair and eye color, and other ‘‘phenotypic’’
characteristics, were also conducted, but the results are not
materially different and are not presented. Hardy-Weinberg
equilibrium (HWE) tests were performed to identify possible
gross systematic genotyping problems; as our control group
consists of melanoma cases, absence of HWE could be
expected in SNPs that confer risk. We evaluated the issue of
multiple comparisons using techniques described by Abramo-
vich and Benjamini.37 We also employed quantile–quantile
(Q–Q) plots38 for comparing the distribution of p values
obtained in the logistic regression against those expected if
the data occurred randomly and not speciﬁcally due to asso-
ciations between SNPs and melanoma risk. All analyses were
performed using SAS statistical software version 9.2 (SAS
Institute, Cary, NC).
Meta-analyses
We conducted a comprehensive, systematic search of the
medical literature to identify relevant studies on cutaneous
melanoma in which genotyping results were available for
each of the SNPs identiﬁed as statistically signiﬁcant in our
study. The literature search was limited to studies in humans,
included all years up to November 2010, and was performed
using the following databases: PubMed, ISI Web of Science,
ISI Web of Knowledge, Cochrane and Embase. Search terms
included Vitamin D Receptor and separately, VDR, in combi-
nation with melanoma, allele, gene, polymorphism and risk.
We searched for publications with frequencies or estimates of
relative risk for cutaneous melanoma with 95% CI. Review
articles were considered as sources of additional relevant cita-
tions. We extracted information on the characteristics of the
study population, study design, year of publication and
source of controls (Supporting Information Table S2). The
homozygous occurrence of the most common allele for each
polymorphism was considered the reference for our analyses.
HWE tests were performed among controls. For one study in
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which genotype frequencies were not reported,20 we con-
tacted the authors to obtain this information. Among the
articles retrieved, two articles17,21 presented overlapping data
on rs731236, and we therefore included results of the report
with the largest number of subjects.21 The variation across
different studies attributable to heterogeneity rather than
chance was assessed using the I2 measure.39 We considered
that heterogeneity was present when the overall I2 p value
was <0.05. Calculation of summary OR, 95% CIs and study
heterogeneity p values for meta-analysis was done in STATA
(version 11.0; STATA Corp, College Station, TX) using the
metan function. Publication bias was evaluated using the
adjusted rank correlation test within the metabias function of
STATA.40
Bioinformatics
The SNPs analyzed in this study do not affect the amino acid
sequence. Therefore, we evaluated their potential functional
relevance on the VDR transcription or activity by searching for
overlaps between the SNP genomic location and transcription
factor binding sites, splice sites, sequences complementary to
miRNA seed regions and by considering conservation across
species. We obtained information from the UCSC’s genome
browser tables (accessed October 2009), and each SNP, when
information was available, was further annotated with conser-
vation information, and miRNA and transcription factor bind-
ing site overlaps. Information on conservation was obtained
from the UCSC’s runs of the PHAST package on primates, ver-
tebrates and mammals. The miRNA annotations were obtained
from Target Scan and information on transcription factor
binding from the binding site conservation across the human/
mouse/rat alignment. Further information can be obtained
from: http://genome.ucsc.edu/cgi-bin/hgTables.41 We also used
an alternative method for detecting potential overlaps between
VDR SNPs and miRNAs. Speciﬁcally, we looked for miRNA
seed regions by searching for exact matches between the two to
seven nucleotide regions of known mature human miRNAs
and the reverse complement of these substrings in the
30untranslated region (UTR) of the VDR gene. Selbach et al.42
has shown that this 6-mer miRNA seed is essential for its func-
tion. Consequently, a SNP located in the miRNA target site,
which is complementary to the miRNA seed region, is likely to
deregulate the expression of the target gene.
Results
Descriptive characteristics of the study participants are pro-
vided in Table 1. The distribution of melanoma risk factors
such as age, gender and number of moles on the back dif-
fered between GEM cases and GEM controls. Further details
on the associations between participants’ characteristics and
melanoma risk in this study have been published elsewhere.43
The individual call rates for the SNPs evaluated in this
study, their distribution in the population according to Hap-
Map_CEU and other databases, and the genotype frequencies
obtained in the GEM cases and controls are shown in Table 2.
After excluding four SNPs with poor assay performance, the
average call rate was 0.98 for the remaining 38 SNPs. For
SNPs rs11568820 and rs7305032, the failure rates were 0.12
and 0.07, respectively. However, the proportion of failures
did not differ signiﬁcantly between cases and controls (p ¼
0.33 and p ¼ 0.34). The proportion of failures was also simi-
lar between cases and controls for SNPs rs2228570 (p ¼
0.85) and rs1544410 (p ¼ 0.33). All other SNPs displayed
failure rates <0.03. Genotype frequencies were similar to
those reported in Single nucleotide Polymorphism Database
(dbSNP) in Caucasians or Europeans (HapMap-CEU or
AFD_EUR_PANEL), with few exceptions (rs11168275,
rs12370156 and rs7305032). For rs11168275, we and others44
Table 1. Selected characteristics of study participants
MPM
(GEM cases)
N (%)
SPM
(GEM controls)
N (%)
Age
<50 169 (14.0) 917 (37.1)
50þ 1,038 (86.0) 1,552 (62.9)
Gender
Male 796 (65.9) 1,277 (51.7)
Female 411 (34.1) 1,192 (48.3)
Breslow thickness (mm)
0 (in situ) 431 (35.7) 0 (0.0)
<1 543 (45.0) 1,666 (67.5)
1–2 108 (8.9) 447 (18.1)
2–4 49 (4.1) 194 (7.9)
>4 74 (6.1) 157 (6.4)
Site
head and neck 295 (24.4) 381 (15.5)
trunk 493 (40.9) 1,091 (44.4)
arms 207 (17.2) 460 (18.7)
legs 210 (17.4) 520 (21.2)
other 2 (0.2) 4 (0.2)
Histology
superﬁcial spreading 352 (29.5) 1,347 (54.6)
nodular melanoma 62 (5.2) 220 (8.9)
lentigo maligna 89 (7.5) 174 (7.1)
in situ 428 (35.9) 0 (0.0)
other 263 (22.0) 726 (29.4)
Number of moles
0–4 390 (33.2) 850 (35.2)
5–10 256 (21.8) 545 (22.5)
11–25 279 (23.8) 530 (21.9)
>25 249 (21.2) 492 (20.4)
Total 1,207 2,469
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Table 2. Genotype frequency of VDR variants in individuals with multiple primary (GEM cases) and single primary (GEM controls) melanoma
and adjusted odds ratios by genotype
Relative
position
Reference
sequence Location1 Genotype
Call
rate (%)
Frequency in
dbSNP (%)2
Cases
N (%)
Controls
N (%)
Odds ratio
(95% CI)3
p
value3
Promoter region
1 rs2071358 1F-29607 CC 98.4 56.7 842 (70.7) 1,656 (68.2) 1 0.1
CA 36.7 314 (26.4) 682 (28.1) 0.91 (0.77–1.08)
AA 6.7 35 (2.9) 89 (3.7) 0.73 (0.47–1.11)
2 rs10875712 1F-26412 GG 98.1 41.7 455 (38.5) 1,005 (41.5) 1 0.02
GC 41.7 554 (46.8) 1088 (44.9) 1.16 (0.99–1.37)
CC 16.7 174 (14.7) 331 (13.7) 1.28 (1.01–1.62)
3 rs6823 1F-25571 CC 98.4 27.1 369 (31.1) 765 (31.5) 1 0.33
CG 52.5 565 (47.6) 1,165 (47.9) 1.04 (0.88–1.24)
GG 20.3 253 (21.3) 500 (20.6) 1.11 (0.90–1.37)
4 rs4760674 1F-20173 CC 98.9 40 424 (35.4) 965 (39.6) 1 0.002
CA 41.7 583 (48.7) 1,110 (45.6) 1.32 (1.12–1.56)
AA 18.3 191 (15.9) 361 (14.8) 1.33 (1.06–1.67)
5 rs1015390 1F-7196 CC 98.9 75 876 (73.3) 1,781 (73.0) 1 0.52
CT 25 291 (24.4) 601 (24.6) 0.94 (0.79–1.12)
TT 28 (2.3) 57 (2.3) 0.96 (0.58–1.58)
6 rs4237856 1F-1198 AA 97.8 65 683 (57.9) 1,363 (56.4) 1 0.22
CA 26.7 427 (36.2) 888 (36.7) 0.94 (0.80–1.10)
CC 8.3 69 (5.9) 166 (6.9) 0.83 (0.60–1.14)
7 rs4073729 1F-217 CC 98.7 70 862 (72.4) 1,780 (73.0) 1 0.89
TC 30 300 (25.2) 604 (24.8) 0.99 (0.83–1.17)
TT 28 (2.4) 55 (2.3) 0.99 (0.60–1.64)
8 rs11168314 1Fþ6225 GG 98.3 68.3 771 (65.0) 1,574 (64.8) 1 0.74
GA 31.7 357 (30.1) 742 (30.5) 0.95 (0.80–1.11)
AA 58 (4.9) 113 (4.7) 1.04 (0.73–1.49)
9 rs10459217 1Fþ20593 TT 98.4 66.7 752 (63.7) 1,545 (63.4) 1 0.68
TC 31.7 372 (31.5) 783 (32.1) 0.93 (0.79–1.10)
CC 1.7 56 (4.7) 110 (4.5) 1.06 (0.74–1.52)
10 rs11568820 1E-1739 GG 88.4 68.3 742 (68.4) 1,512 (69.9) 1 0.79
Cdx2 AG 30 295 (27.2) 559 (25.8) 0.97 (0.81–1.16)
AA 1.7 48 (4.4) 93 (4.3) 1.18 (0.79–1.75)
11 rs7139166 1A-1521 CC 97 30 381 (32.7) 814 (33.9) 1 0.04
GC 50 534 (45.8) 1,137 (47.4) 1.06 (0.89–1.26)
GG 20 251 (21.5) 450 (18.7) 1.26 (1.02–1.56)
12 rs4516035 1A-1012 TT(AA) 98.5 30 382 (32.2) 816 (33.5) 1 0.05
EcoRV CT(GA) 50 551 (46.5) 1,165 (47.8) 1.07 (0.90–1.26)
CC(GG) 20 252 (21.3) 454 (18.6) 1.25 (1.01–1.55)
13 rs7299460 1Dþ2175 CC 98.1 45.8 593 (50.1) 1,189 (49.1) 1 0.99
(1B-2528) CT 49.2 466 (39.4) 1,000 (41.3) 0.96 (0.82–1.13)
TT 5.1 125 (10.6) 234 (9.7) 1.04 (0.81–1.35)
14 rs11168287 12516 GG 98.1 16.7 292 (24.6) 639 (26.4) 1 0.03
AG 50 577 (48.7) 1,187 (49.0) 1.16 (0.97–1.40)
AA 33.3 316 (26.7) 594 (24.5) 1.27 (1.03–1.57)
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Table 2. Genotype frequency of VDR variants in individuals with multiple primary (GEM cases) and single primary (GEM controls) melanoma
and adjusted odds ratios by genotype (Continued)
Relative
position
Reference
sequence Location1 Genotype
Call
rate (%)
Frequency in
dbSNP (%)2
Cases
N (%)
Controls
N (%)
Odds ratio
(95% CI)3
p
value3
15 rs11168284 10151 AA 98.1 n/a 501 (42.4) 979 (40.4) 1 0.37
GA 534 (45.2) 1,146 (47.3) 0.93 (0.79–1.10)
GG 146 (12.4) 299 (12.3) 0.92 (0.72–1.17)
16 rs10875694 8762 TT 99.6 n/a 836 (69.5) 1,703 (69.3) 1 0.82
TA 331 (27.5) 671 (27.3) 1.03 (0.87–1.22)
AA 36 (3.0) 84 (3.4) 0.83 (0.54–1.28)
17 rs4760648 7767 CC 98.5 25 405 (34.1) 726 (29.9) 1 0.06
CT 56.7 569 (47.9) 1,262 (51.9) 0.83 (0.70–0.98)
TT 18.3 215 (18.1) 444 (18.3) 0.84 (0.67–1.04)
18 rs2238135 5292 GG 99 60.6 711 (59.3) 1,388 (56.8) 1 0.18
(1C-1663) GC 31 414 (34.6) 895 (36.6) 0.93 (0.79–1.09)
CC 8.5 73 (6.1) 160 (6.5) 0.84 (0.61–1.15)
19 rs1989969 5112 CC 99.3 43.7 417 (34.8) 923 (37.6) 1 0.08
(1C-1453) CT 46.5 574 (48.0) 1,151 (46.9) 1.16 (0.98–1.37)
TT 9.9 206 (17.2) 378 (15.4) 1.18 (0.94–1.47)
Coding region
20 rs2228570 Start-3 CC (FF) 95 35 421 (36.7) 873 (37.2) 1 0.71
FokI (Ex2) CT (Ff) 41.7 548 (47.8) 1,117 (47.6) 1.01 (0.85–1.19)
TT (ff) 23.3 177 (15.4) 355 (15.1) 1.05 (0.83–1.33)
21 rs11168275 Intron 2þ476 AA 99.5 3.34 687 (57.1) 1,401 (57.1) 1 0.87
GA 33.34 445 (37.0) 899(36.6) 1.01 (0.86–1.18)
GG 63.34 71 (5.9) 155 (6.3) 0.94 (0.68–1.29)
22 rs7974708 Intron 2þ2586 TT 98.9 480 (40.1) 1,047 (42.9) 1 0.11
CT n/a 558 (46.6) 1,127 (46.2) 1.07 (0.91–1.25)
CC 159 (13.3) 265 (10.9) 1.22 (0.96–1.56)
23 rs3782905 Intron 2þ6584 CC 99 53.3 523 (43.7) 1,128 (46.2) 1 0.08
CG 36.7 529 (44.2) 1,083 (44.3) 1.08 (0.92–1.26)
GG 10 145 (12.1) 233 (9.5) 1.25 (0.97–1.60)
24 rs2189480 Intron 2þ8923 CC 98.1 40 514 (43.4) 986 (40.7) 1 0.08
CA 41.7 518 (43.8) 1,100 (45.4) 0.89 (0.76–1.05)
AA 18.3 152 (12.8) 337 (13.9) 0.84 (0.66–1.06)
25 rs886441 Intron 2þ4004 TT 98.5 66.7 793 (66.8) 1,574 (64.7) 1 0.64
CT 28.3 344 (29.0) 754 (31.0) 0.95 (0.81–1.12)
CC 5 50 (4.2) 106 (4.4) 0.98 (0.68–1.43)
26 rs2239181 Intron 3þ2881 TT 98.8 80 972 (81.3) 1,938 (79.6) 1 0.47
GT 18.3 214 (17.9) 474 (19.5) 0.95 (0.78–1.15)
GG 1.7 9 (0.8) 24 (1.0) 0.79 (0.34–1.82)
27 rs2107301 Intron 3þ3260 CC 98.9 48.3 649 (54.2) 1,253 (51.4) 1 0.32
CT 46.7 461 (38.5) 995 (40.8) 0.94 (0.80–1.10)
TT 5 87 (7.3) 190 (7.8) 0.89 (0.66–1.19)
28 rs2239182 Intron 3þ3419 GG 97 25 354 (30.2) 644 (26.9) 1 0.08
AG 46.7 555 (47.4) 1,170 (48.9) 0.89 (0.74–1.06)
AA 28.3 263 (22.4) 579 (24.2) 0.83 (0.67–1.03)
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have found that G, and not A, is the minor allele in Cauca-
sians. All three SNPs are in HWE (Supporting Information
Table S1). The following SNPs were in LD with each other
(D0 > 0.96): rs7139166 and rs4516035 (D0 ¼ 0.972; R2 ¼
0.942); rs2544027 and rs2544028 (D0 ¼ 0.968, R2 ¼ 0.708);
rs2544027 and rs2544038 (D0 ¼ 0.974, R2 ¼ 0.815);
rs2544028 and rs2544038 (D0 ¼ 0.974, R2 ¼ 0.815);
rs1544410 and rs731236 (D0 ¼ 0.957, R2 ¼ 0.912).
The genotype distribution among cases and controls, and
the relative risks based on individual VDR genotypes are pre-
sented in Table 2. Nominally signiﬁcant results (at the 5%
signiﬁcance level) are in bold type. Eight SNPs displayed stat-
istically signiﬁcant associations (p value for trend p  0.05)
after adjusting for age, sex, age–sex interaction and study
center. The estimated increase in risk for individuals who
were homozygous for the variant allele ranged from 25 to
33% for six polymorphisms: rs10875712, rs4760674,
rs7139166, rs4516035, rs11168287 and rs1544410; for two
polymorphisms, homozygous variant carriers had a decreased
risk: rs7305032 and rs7965281. Results of all signiﬁcant and
Table 2. Genotype frequency of VDR variants in individuals with multiple primary (GEM cases) and single primary (GEM controls) melanoma
and adjusted odds ratios by genotype (Continued)
Relative
position
Reference
sequence Location1 Genotype
Call
rate (%)
Frequency in
dbSNP (%)2
Cases
N (%)
Controls
N (%)
Odds ratio
(95% CI)3
p
value3
29 rs12370156 Intron 3þ4697 TT 98.7 25 337 (28.2) 641 (26.4) 1 0.33
CT 37.5 576 (48.2) 1,179 (48.5) 0.90 (0.76–1.08)
CC 37.5 283 (23.7) 612 (25.2) 0.90 (0.73–1.11)
30 rs2238140 Intron 3þ6166 TT 98.9 339 (28.4) 637 (26.1) 1 0.23
CT n/a 573 (47.9) 1,193 (48.9) 0.88 (0.74–1.05)
CC 283 (23.7) 612 (25.1) 0.88 (0.72–1.09)
31 rs7305032 Intron 5þ1052 AA 93.3 41.7 351 (30.7) 612 (26.7) 1 0.05
AG 36.7 577 (50.5) 1,197 (52.3) 0.83 (0.70–0.99)
GG 21.7 214 (18.7) 479 (20.9) 0.81 (0.65–1.02)
32 rs1544410 Intron 8 GG (bb) 95.8 35 390 (34.2) 881 (37.0) 1 0.03
BsmI (Ex8þ284) GA (bB) 41.7 534 (46.8) 1,136 (47.7) 1.05 (0.89–1.25)
AA (BB) 23.3 216 (18.9) 363 (15.3) 1.30 (1.04–1.63)
33 rs731236 Exon 9–32 TT (TT) 97.9 34.5 407 (34.5) 897 (37.1) 1 0.06
TaqI TC (Tt) 43.1 544 (46.1) 1,140 (47.1) 1.01 (0.86–1.20)
CC (tt) 22.4 229 (19.4) 381 (15.8) 1.27 (1.02–1.58)
30 UTR
34 rs11574139 Ex9þ3234 AA 99 95.4 1,107 (92.7) 2,269 (92.8) 1 0.76
(U-2978) TA 4.6 85 (7.1) 168 (6.9) 1.12 (0.83–1.50)
TT 2 (0.2) 8 (0.3) 0.46 (0.09–2.34)
35 rs7965281 UTRþ3713 GG 93.8 36.7 292 (25.8) 545 (23.5) 1 0.04
AG 40 623 (55.1) 1,271 (54.9) 0.87 (0.72–1.04)
AA 23.3 215 (19.0) 501 (21.6) 0.78 (0.62–0.99)
36 rs2544027 UTRþ18799 CC 99 318 (26.6) 691 (28.3) 1 0.16
CT n/a 562 (47.0) 1,154 (47.2) 1.15 (0.96–1.37)
TT 315 (26.4) 601 (24.6) 1.16 (0.94–1.42)
37 rs2544028 UTRþ18898 TT 98.5 40 401 (33.7) 872 (35.9) 1 0.08
TA 45 550 (46.2) 1,129 (46.4) 1.10 (0.93–1.30)
AA 15 239 (20.1) 430 (17.7) 1.21 (0.98–1.50)
38 rs2544038 UTRþ20095 TT 98.1 365 (31.0) 780 (32.1) 1 0.26
CT n/a 544 (46.2) 1,145 (47.1) 1.08 (0.91–1.28)
CC 269 (22.8) 505 (20.8) 1.12 (0.91–1.39)
1Positions according to Nejentsev et al.12 and Fang et al.13 2Genotype frequencies were obtained from HapMap-CEU, AFD_EUR_PANEL or VDR-LD-
Caucasian. 3Adjusted for age, sex, age–sex interaction and study center. Signiﬁcant associations (p values for trend < 0.05) are shown in bold font.
4Our study and the recent report44 found that G is the minor allele in Caucasians.
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marginally signiﬁcant SNPs are displayed in Figure 1, in
which the eight signiﬁcant SNPs appear in bold typeface. Fig-
ure 2 depicts the Q–Q plot, which should track with the 45
line in the absence of association across the locus. The shape
of the curve exhibits a strong departure from what we would
expect in the absence of association. Five promoter SNPs,
two coding SNPs and one 30UTR SNP showed signiﬁcant
associations. With respect to haplotype blocks described pre-
viously, ﬁve of the signiﬁcant SNPs lie within ‘‘block C’’ and
two of these overlap with ‘‘block 2’’;13 whereas three SNPs lie
within block B.12
The VDR SNPs tested in this study included promoter,
intronic and 30UTR variants and therefore do not directly
affect the protein sequence. We evaluated their potential
functional signiﬁcance by searching for overlaps between
genomic localization of SNPs and putative transcription fac-
tor binding sites and miRNA seed regions. We also evaluated
the conservation across species. We found that rs2228570
localizes to a nucleotide conserved among primates, verte-
brates and mammals (conservation scores 392, 418 and 379,
respectively); SNPs rs731236 and rs2544028 localize to nucle-
otides conserved among vertebrates (conservation scores 272
and 480, respectively) and mammals (conservation scores 275
and 443, respectively); and SNPs rs4073729 and rs731236
localize to nucleotides conserved among primates (conserva-
tion scores of 293 and 407, respectively). The genomic loca-
tions of two SNPs overlap with transcription factor binding
sites: rs4237856 (V$HNF4_01 HNF-4alpha 1 and 2, tran-
scription z-score 1.98; and V$PPARG_01 Peroxisome Prolif-
erator-activated Receptor (PPAR)gamma, transcription z-
score 2.58) and rs1544410 (V$IK3_01 Ikaros 3, transcription
z-score 2.77; and V$IK1_01 Ikaros 1, transcription z-score
2.14), although the z-scores for HNF-4alpha 1 and 2 and for
Ikaros 1 fall below the threshold of 2.33. SNP rs11568820 is
known to interfere with the binding site of the transcription
factor Cdx2.11 We did not ﬁnd any overlaps with seed
regions of known miRNAs.
At the time of the preparation of this article, 13 original
reports addressed VDR SNPs and the risk of melanoma, and
11 articles containing a total of 13 series reported results for
three of our signiﬁcant or borderline signiﬁcant SNPs:
rs4516035, rs1544410 and rs731236. Of these, two reports
overlapped with a subsequent publication from the same
investigators and were not considered for the current meta-
Figure 1. Position of the SNPs studied in GEM in relation to the VDR structure. SNPs with signiﬁcant associations in multivariate analyses
after adjusting for age, sex, age–sex interaction and study center are shown in bold font. The vertical bars represent promoters 1F–1C
(green) and exons (blue). The numbers 1–38 refer to the SNP’s relative position from 50 to 30 (Table 2). The polymorphism TaqI is located
near the stop codon on exon 9; however, it is strongly linked to the 30 regulatory region. The grey box represents the 30 UTR.
Figure 2. Uniform Q–Q Plot for the VDR SNPs risk trend p values.
Quantiles of the obtained p values (þ) were plotted against the
theoretical uniform quantiles.
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analyses.17,21 The main study characteristics and the distribu-
tion of genotypes among cases and controls are listed in the
Supporting Information (Tables S2 and S3). The individual
unadjusted ORs and summary odds ratio for heterozygotes
and for carriers of the homozygote variant compared to the
homozygote common allele are presented in Table 3 and in
Figure 3.
For studies that addressed rs4516035 (1A-1012), the
adjustment for covariates varied substantially. Speciﬁcally,
four studies18,19,22,23 matched cases and controls by age and
gender, three studies14,15,21 included age and sex in multivari-
ate analyses, whereas one study20 adjusted for phenotypic fea-
tures. The variant allele G produces a null association with
melanoma. There was evidence of heterogeneity for the
observed risks of the homozygous variant (p ¼ 0.04) but not
for heterozygote (p ¼ 0.31) and no evidence of publication
bias (p ¼ 0.88 and p ¼ 0.65, respectively). For rs1544410
(BsmI), the allele A (B) showed a statistically negative associ-
ation with melanoma (Fig. 3b; Table 3). There was no evi-
dence of heterogeneity for the observed risks of the heterozy-
gous variant (p ¼ 0.78) or for the homozygote variant (p ¼
0.18), and no evidence of publication bias (p ¼ 0.45 and p ¼
0.45, respectively). The rs731236 (TaqI) allele C (t) showed a
statistically nonsigniﬁcant negative association with mela-
noma (Fig. 3c; Table 3). There was evidence of heterogeneity
for the observed risks of the heterozygous variant (p ¼ 0.03)
but not for the heterozygote variant (p ¼ 0.10) and no evi-
dence of publication bias (p ¼ 0.19 and p ¼ 0.85, respec-
tively). We did not observe departure from HWE in any of
the series (Table S3).
Discussion
In this large population based case-control study comprising
3,676 people with incident single and multiple primary
Table 3. Individual odds ratios and summary odds ratios for heterozygote and homozygote variants versus common alleles for SNPs
rs4516035 and rs731236
rs4516035 Study (series)
OR (95% CI)
TC(AG) vs. TT(AA) Wt %
OR (95% CI)
CC(GG) vs. TT(AA) Wt %
Gapska et al.22 (CC1) 0.86 (0.68–1.09) 29.94 0.95 (0.71–1.28) 29.1
Randerson-Moor et al.23 (CC1) 1.10 (0.85–1.43) 21.19 0.96 (0.69–1.34) 22.29
Randerson-Moor et al.23 (CC2) 1.32 (0.95–1.82) 12.76 1.37 (0.92–2.06) 12.38
Barroso et al.20 1.08 (0.73–1.60) 9.38 1.51 (0.90–2.53) 7.38
Povey et al.18 (CC1) 1.01 (0.76–1.34) 18.3 0.79 (0.55–1.14) 20.61
Santonocito et al.19 1.39 (0.76–2.54) 3.54 1.42 (0.60–3.37) 2.7
Halsall et al.15 0.73 (0.40–1.34) 4.89 0.33 (0.14–0.78) 5.54
Summary 1.03 (0.91–1.16) 100 0.99 (0.85–1.16) 100
rs1544410 Study (series)
OR (95% CI)
GA (bB) vs. GG (bb) Wt %
OR (95% CI)
AA (BB) vs. GG (bb) Wt %
Gapska et al.22 (CC1) 0.91 (0.73–1.13) 25.83 0.92 (0.67–1.27) 21.6
Randerson-Moor et al.23 (CC1) 0.93 (0.72–1.20) 18.01 1.00 (0.71–1.41) 17.96
Randerson-Moor et al.23 (CC2) 0.81 (0.59–1.11) 13.03 0.69 (0.45–1.05) 14.44
Li et al.21 0.74 (0.60–0.92) 28.45 0.78 (0.59–1.04) 29.77
Santonocito et al.19 0.74 (0.40–1.40) 3.34 0.29 (0.12–0.71) 5.12
Han et al.16 0.87 (0.62–1.20) 11.33 0.82 (0.51–1.31) 11.11
Summary 0.84 (0.75–0.94) 100 0.82 (0.70–0.95) 100
rs731236 Study (series)
OR (95% CI)
TC(Tt) vs. CC(tt) Wt %
OR (95% CI)
TT (TT) vs. CC (tt) Wt %
Gapska et al.22 (CC1) 1.03 (0.83–1.28) 25.78 1.10 (0.79–1.53) 20.28
Randerson-Moor et al.23 (CC1) 0.97 (0.75–1.26) 18.83 1.07 (0.76–1.51) 18.86
Randerson-Moor et al.23 (CC2) 0.96 (0.70–1.31) 12.76 0.73 (0.48–1.13) 14.74
Barroso et al.20 1.26 (0.85–1.87) 6.91 1.09 (0.64–1.84) 7.98
Li et al.21 0.69 (0.55–0.85) 31.71 0.65 (0.49–0.87) 34.21
Hutchinson et al.14 1.29 (0.77–2.15) 4.01 1.28 (0.62–2.65) 3.95
Summary 0.93 (0.83–1.04) 100 0.89 (0.76–1.04) 100
Weights were calculated using Mantel-Haenszel methods and represent the individual contribution of each study to the overall OR.
CC1 or CC2, case-control series; OR, unadjusted odds ratio; CI, conﬁdence intervals.
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melanoma we evaluated 38 VDR gene SNPs for their impact
in the development of skin melanoma and found that in
addition to the BsmI (rs1544410), seven SNPs (rs10875712,
rs4760674, rs7139166, rs4516035, rs11168287, rs7305032 and
rs7965281) were signiﬁcantly associated with risk. Because we
conducted 38 individual statistical tests, we recognize the
increased risk of false positive ﬁndings due to these ‘‘multiple
comparisons’’; we would expect about two of the tests to be
signiﬁcant simply due to chance. The fact that we observed
eigth signiﬁcant SNPs, reﬂected by the skewness in the Q–Q
plot (Fig. 2), suggests that the evidence broadly favors the hy-
pothesis that the gene harbors at least some causal variants.
Promoter SNPs
Most of the VDR SNPs identiﬁed in the last several years are
of unknown functional signiﬁcance; however, in vitro studies
suggest that at least some SNPs affect the VDR mRNA and/
or protein levels.13,24,25,26 Such is the case for two of the
Figure 3. Meta-analysis of VDR SNPs reported in other investigations of melanoma in relation to risk. (a) SNP rs4516035 (variant allele G),
(b) SNP rs1544410 (variant allele A or ‘‘B’’) and (c) SNP rs731236 (variant allele C or ‘‘t’’). Unadjusted ORs and 95% CI are shown.
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SNPs possibly associated with multiple primary melanoma in
our study: rs7139166 and rs4516035, located in the promoter
region in positions 1A-1521 and 1A-1012. The genotype fre-
quencies in our study are similar to those reported in dbSNP
in Caucasians and to those reported by others for
rs4516035.15,18,22,23,45 These two neighboring SNPs are in
strong LD (D0 ¼ 0.968); therefore, it is not surprising that
the genotype frequencies and the ORs conferred by each of
the minor alleles are very similar in our study (Table 2). A
previous report suggested a link between these SNPs and
stature,31 although results from a larger study did not sup-
port this ﬁnding.46 We found that the G allele of rs4516035
appears to confer risk. Recently, Randerson-Moor et al.23 in a
population-based study of 1,028 melanoma cases and 402
controls found no association for rs4516035, whereas in a
second case-control study of 299 melanoma cases and 560
unaffected females, the authors reported an increased risk
associated with the same allele (G), though the results fall
short of statistical signiﬁcance. We further compared our
results to those obtained in our meta-analysis of a total of six
published reports on this SNP and melanoma and found no
evidence overall that this SNP is associated with melanoma
risk, although the results are inconsistent, with signiﬁcant
heterogeneity in the observed relative risks across studies.
Our ﬁndings are consistent with the in vitro data for
rs4516035.13,31 Speciﬁcally, d’Alesio et al.31 observed that one
base-change in any of the two variant sites located in posi-
tions 1A-1521 or 1A-1012 led to a dramatic change in pro-
tein-DNA complex formation, and that the promoter activity
of the VDR was nearly doubled in cells carrying the haplo-
type rs7139166-G/rs4516035-A, when compared to those
with the rs7139166-C/rs4516035-G haplotype.
It has been recently hypothesized that the A allele in posi-
tion 1A-1012 (rs4516035) indirectly promotes a GATA-3
driven T-cell switch of naı¨ve T cells to T-helper 2 cells and
that this allele may play different roles in susceptibility and
in metastasis possibly as a function of the transcription fac-
tors secreted by different cellular backgrounds.13,45,47 Our
results do not support an adverse role of the allele ‘‘A’’ in
position 1A-1012 in relation to melanoma risk, and in sup-
port of our ﬁndings, the qualitative analyses of the meta-
analyses conducted on published melanoma case-control se-
ries suggests that ‘‘G’’ may represent the risk allele.
We found four signiﬁcant VDR promoter SNPs
(rs10875712, rs4760674, rs7139166 and rs11168287) that
have not been reported previously in relation to melanoma
risk or progression.
Coding region and 30UTR SNPs
Three adjacent Restriction fragment length polymorphism
(RFLP) SNPs for BsmI (rs1544410), ApaI (rs7975232) and
TaqI (rs731236), respectively, at the 30 end of the gene have
been the most frequently studied in cancer and in melanoma.
The functional characterization of these SNPs has produced
inconsistent results across studies, and if these SNPs are non-
functional, the effect observed in some investigations may be
due to truly relevant SNPs in strong LD located elsewhere in
the gene. Here, we report that in this gene region, in addition
to the minor allele of the BsmI polymorphism (rs1544410),
which increases risk, the minor allele of rs7965281, a SNP
which has never been studied in relation to melanoma prior
to this work, seems to confer some reduction in risk. We also
report that two additional SNPs in this location may modify
risk: rs7305032, which was not reported previously in relation
to melanoma, and rs731236 (TaqI), although the latter, which
is in high LD with BsmI and maps to a nucleotide conserved
across species, exhibited only borderline signiﬁcance (p value
0.06; Table 2). Some investigations targeted to determine the
expression differences for polymorphisms in the 30 end of the
VDR gene have shown higher levels of mRNA expression for
the BsmI-ApaI-TaqI haplotype BAt (rs1544410-A/rs7975232-
A/rs731236-C) than for the haplotype baT(rs1544410-G/
rs7975232-C/rs731236-T); however, the opposite results have
been found not only for the VDR mRNA expression but also
for the mRNA stability and transactivation in human ﬁbro-
blasts, and in leukemia and prostate cancer cell lines.11 Our
ﬁndings for rs1544410 suggest that the A (B) might be the
adverse allele in relation to melanoma risk, which differs
from what other studies have found with one excep-
tion.16,19,21–23 Speciﬁcally, three studies were null, one study
reported reduction of risk in heterozygous bB individuals but
not in homozygotes BB and one small hospital-based study
conducted in 101 cases and 101 controls found a protective
effect for the B allele; it is of note that the reported MAF
among controls was higher than the one reported in dbSNP
and in other studies including ours. A more recent popula-
tion-based study of 763 cases and 763 controls conducted in
a Polish population found that haplotypes containing the B
allele increased risk for melanoma.22 Results from our meta-
analysis conducted on ﬁve previously published studies, like
in previous meta-analyses,23,27,28 suggest a protective role for
the B allele; however, considering the results from our large
study after adjusting for covariates, we argue that the results
from the meta-analyses should be considered with caution
and that BsmI should be further characterized in large popu-
lation-ascertained cohorts and in functional assays preferen-
tially using melanoma and/or skin models. Our ﬁndings for
rs731236 suggest that the C (t) allele might be the adverse al-
lele in relation to melanoma risk. Recent reports have found
similar genotype frequencies to those in our work; however,
investigators found either no signiﬁcant associations with
melanoma for rs73123614,20,22,23 or, in one study, a signiﬁcant
association for the contralateral allele T (T).21 Our meta-anal-
ysis conducted on ﬁve publications does not provide sufﬁ-
cient evidence for an effect of this SNP and melanoma; how-
ever, it is important to note that our meta-analyses were
unadjusted for covariates, and that the results may differ in a
multivariate logistic regression.
In relation to bioinformatics predictions, there are two
opposing theories concerning conservation of sequences
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across species in regards to functional relevance. The ﬁrst
supports the idea of a plausible biological function, and as an
extension of this idea, one would expect to uncover mela-
noma risk SNPs in this region. A second opposing hypothesis
proposes that variants in a conserved region are subjected to
negative selection, and those that persist will more likely be
non functional. Interestingly, two of the investigated SNPs
(rs731236 and rs2544028) are located on the boundary of the
conserved region and although the associations do not reach
statistical signiﬁcance, the variants increase the risk by 21–
27% (p values 0.06 and 0.08, respectively). SNP rs11568820
has been extensively characterized in in vitro studies and
overlaps with the binding site of Cdx2. One would expect to
ﬁnd a signiﬁcant role for this polymorphism in melanoma
risk; however, it is possible that its effect is cell-speciﬁc. In
fact, Cdx2 is differentially expressed in normal stomach and
intestine and seems progressively decreased in gastric intesti-
nal metaplasia, dysplasia and cancer.17,48,49 SNP rs4237856
overlaps with the binding site of PPAR-gamma. The PPARs
are known to heterodimerize with the retinoid X receptor
and with the vitamin D bound to its receptor. PPARs may be
of importance in cell growth regulation in melanocytes; how-
ever, expression of PPAR-gamma is much weaker in melano-
cytes, at least based on observations in MeWo cells;50 there-
fore, one could speculate that even if this SNP can facilitate
or hinder the binding of PPAR-gamma, the contribution of
this binding in melanoma risk may not be as signiﬁcant as
with other PPARs.
A major limitation so far of association studies using VDR
SNPs in relation to complex-diseases such as cancer is the
limited number of variants studied. The VDR gene is very
polymorphic; however, information on the existing gene var-
iants was initially available from the rather insensitive search
of polymorphic patterns within a limited region using restric-
tion enzymes. Additional polymorphisms have been identiﬁed
during the search for mutation in tumors.24 In more recent
years, the studies of Nejentsev et al.12 and Fang et al.13 have
contributed to the ﬁeld by systematically scanning and char-
acterizing variations across the entire VDR gene and by
describing patterns of LD between alleles in different ethnic
groups. The main strengths of our study are the comprehen-
sive evaluation of VDR and the large number of study sub-
jects, as well as the availability of data on known melanoma
risk confounders. The overall effect on melanoma risk found
here was small. Furthermore, the results overall do not reach
signiﬁcance if evaluated either by the Bonferroni correction or
by restricting the false discovery rate to 5%.37 However, eight
of 38 (~21%) investigated SNPs revealed statistically signiﬁcant
associations at the 5% signiﬁcance level (vs. 1.9 expected) and
16 of 38 are signiﬁcant at the 10% level (vs. 3.8 expected) pro-
portions considerably higher than would be expected if there
is in fact no association between VDR genotype and mela-
noma risk. Thus, we believe that the results, collectively, are
strongly suggestive that VDR is a risk locus for melanoma.
Our case-control study design was novel because the con-
trols have melanoma and the cases are required to have expe-
rienced melanoma twice. The premise is that the risk factors
that affect melanoma must affect the occurrence of a second
melanoma in a population of individuals with melanoma,
and this is borne out empirically in earlier results from our
and other studies, although there is evidence that the magni-
tude of the observed relative risks may be attenuated.29 The
rationale for this design is that it delivers much greater statis-
tical power for the evaluation of rare, strong risk factors than
a conventional case-control design with healthy controls.30 In
such a design, the double primary cases are typically older
than the single primary controls, and in the case of mela-
noma, the gender distribution is altered because of the strong
interaction between age and gender on melanoma incidence,
and so we adjusted for these factors in our analyses. A fur-
ther complication is that many second primaries are detected
as in situ lesions because of the careful clinical surveillance
that melanoma patients experience, and we elected to include
these individuals as cases on the assumption that they would
ultimately have been diagnosed with an invasive lesion.
In summary, we found that eight VDR SNPs, located in
the promoter, coding and 30 gene regions, were associated
with melanoma and confer a modest but statistically signiﬁ-
cant increased (rs10875712, rs4760674, rs7139166, rs4516035,
rs11168287 and rs1544410) or decreased (rs7305032 and
rs7965281) risk of becoming a multiple primary melanoma.
To our knowledge, this constitutes the largest study of VDR
polymorphisms in melanoma to date. Our results provide
some evidence in support of the hypothesis that the vitamin
D pathway may play an important role in melanoma genesis.
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